India's GLP-1 Weight-Loss Drug Market Expected to Grow -- Market Talk

Dow Jones

Dec 23, 2025

0610 GMT - India's market for GLP-1 weight-loss drugs is valued at several billion dollars and could grow to 4%-5% of the country's pharmaceutical market, Elarna Capital strategist Bino Pathiparampil says in a note. Semaglutide's sales volume is expected to surge as the GLP-1 drug goes generic in India next year, with the drug's wider use potentially adding 1%-2% to India's pharma sector growth, he says. Generic drugmakers with strong existing diabetes franchises are set to benefit the most, the strategist says, with Sun Pharmaceutical Industries, Lupin, Eris Lifesciences, Torrent Pharmaceuticals and Intas Pharmaceuticals best positioned. Dr. Reddy's and Zydus Life may also benefit, he adds. However, growth in GLP-1 treatments might cause other diabetes products to suffer, with the insulin market potentially shrinking by 10%-15%. (jason.chau@wsj.com)

(END) Dow Jones Newswires

December 23, 2025 01:10 ET (06:10 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2593616444"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2593616444\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2593616444?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-23 14:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593616444","market":"us","top_or_hot":-1,"title":"India's GLP-1 Weight-Loss Drug Market Expected to Grow -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0610 GMT - India's market for GLP-1 weight-loss drugs is valued at several billion dollars and could grow to 4%-5% of the country's pharmaceutical market, Elarna Capital strategist Bino Pathiparampil says in a note. Semaglutide's sales volume is expected to surge as the GLP-1 drug goes generic in India next year, with the drug's wider use potentially adding 1%-2% to India's pharma sector growth, he says. Generic drugmakers with strong existing diabetes franchises are set to benefit the most, the strategist says, with Sun Pharmaceutical Industries, Lupin, Eris Lifesciences, Torrent Pharmaceuticals and Intas Pharmaceuticals best positioned. Dr. Reddy's and Zydus Life may also benefit, he adds. However, growth in GLP-1 treatments might cause other diabetes products to suffer, with the insulin market potentially shrinking by 10%-15%. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 23, 2025 01:10 ET (06:10 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>India's GLP-1 Weight-Loss Drug Market Expected to Grow -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIndia's GLP-1 Weight-Loss Drug Market Expected to Grow -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-23 14:10</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0610 GMT - India's market for GLP-1 weight-loss drugs is valued at several billion dollars and could grow to 4%-5% of the country's pharmaceutical market, Elarna Capital strategist Bino Pathiparampil says in a note. Semaglutide's sales volume is expected to surge as the GLP-1 drug goes generic in India next year, with the drug's wider use potentially adding 1%-2% to India's pharma sector growth, he says. Generic drugmakers with strong existing diabetes franchises are set to benefit the most, the strategist says, with Sun Pharmaceutical Industries, Lupin, Eris Lifesciences, Torrent Pharmaceuticals and Intas Pharmaceuticals best positioned. Dr. Reddy's and Zydus Life may also benefit, he adds. However, growth in GLP-1 treatments might cause other diabetes products to suffer, with the insulin market potentially shrinking by 10%-15%. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 23, 2025 01:10 ET (06:10 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4590","symbol_name":"PTP","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2593616444","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593616444","pubTimestamp":1766470200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0610 GMT - India's market for GLP-1 weight-loss drugs is valued at several billion dollars and could grow to 4%-5% of the country's pharmaceutical market, Elarna Capital strategist Bino Pathiparampil says in a note. Semaglutide's sales volume is expected to surge as the GLP-1 drug goes generic in India next year, with the drug's wider use potentially adding 1%-2% to India's pharma sector growth, he says. Generic drugmakers with strong existing diabetes franchises are set to benefit the most, the strategist says, with Sun Pharmaceutical Industries, Lupin, Eris Lifesciences, Torrent Pharmaceuticals and Intas Pharmaceuticals best positioned. Dr. Reddy's and Zydus Life may also benefit, he adds. However, growth in GLP-1 treatments might cause other diabetes products to suffer, with the insulin market potentially shrinking by 10%-15%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4590":"PTP","BK4144":"石油与天然气的储存和运输","GLP":"Global Partners Lp"},"translate_title":"印度GLP-1减肥药市场有望增长--市场谈","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLP":1.5,"MNDmain":1.5},"content_text":"0610 GMT - India's market for GLP-1 weight-loss drugs is valued at several billion dollars and could grow to 4%-5% of the country's pharmaceutical market, Elarna Capital strategist Bino Pathiparampil says in a note. Semaglutide's sales volume is expected to surge as the GLP-1 drug goes generic in India next year, with the drug's wider use potentially adding 1%-2% to India's pharma sector growth, he says. Generic drugmakers with strong existing diabetes franchises are set to benefit the most, the strategist says, with Sun Pharmaceutical Industries, Lupin, Eris Lifesciences, Torrent Pharmaceuticals and Intas Pharmaceuticals best positioned. Dr. Reddy's and Zydus Life may also benefit, he adds. However, growth in GLP-1 treatments might cause other diabetes products to suffer, with the insulin market potentially shrinking by 10%-15%. (jason.chau@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 23, 2025 01:10 ET (06:10 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}